| Field | Specification |
|---|---|
| Target | |
| Alternative names | Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1; D-fructose-6-phosphate amidotransferase 1; Glutamine:fructose-6-phosphate amidotransferase 1; GFAT 1; GFAT1; Hexosephosphate aminotransferase 1; GFPT1; GFAT; GFPT |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human GFPT1, identical to the related mouse and rat sequences. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects glutamine--fructose-6-phosphate aminotransferase (gene GFPT1) in human and rat samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 78.8 kDa, and the supplier reports an observed band at about 79 kDa.
GFPT1 (GFAT1) controls the first, rate-limiting step of hexosamine biosynthesis. It uses glutamine to convert fructose-6-phosphate into glucosamine-6-phosphate, controlling production of UDP-GlcNAc for glycosylation, and it is feedback-inhibited by UDP-GlcNAc. GFPT1 mutations cause a congenital myasthenic syndrome, and the enzyme is studied in nutrient sensing and O-GlcNAc signaling.
| Target | Glutamine--fructose-6-phosphate aminotransferase (gene GFPT1; UniProt Q06210, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 78.8 kDa |
| Observed MW | 79 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human, Rat) |
Samples with a confirmed band (WB): human HepG2 cells, human HeLa cells, human 293T cells, human MCF-7 cells, human Caco-2 cells, human HEL cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human colon adenocarcinoma tissue, human liver cancer tissue, human cervical cancer tissue, human lung cancer tissue, human tonsil tissue, human lienal rupture tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): Caco-2 cells.
Samples with a confirmed signal (flow cytometry): Caco-2 cells, NRK cells.
Immunogen
Synthetic peptide from the C-terminal region of human GFPT1. The peptide sequence is conserved in mouse and rat.
Reactivity Notes
The supplier lists reactivity with human and rat. Tissue expression noted by UniProt (human): Predominantly expressed in skeletal muscle. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Zhongyu Li et al. (2020) Nanoparticle depots for controlled and sustained gene delivery. Journal of Controlled Release. 10.1016/j.jconrel.2020.03.021
